News

EurekAlert!7d
GLP-1 receptor agonists in idiopathic intracranial hypertension
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy in idiopathic intracranial hypertension is associated with significant reductions in medication use, symptoms/signs, and procedural ...
The American Journal of Managed Care9d
GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer
Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and ...
HealthDay on MSN2d
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors ...
BioWorld7d
Oral dual GLP-1/glucagon receptor agonist peptide shows favorable preclinical profile
Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...
Dr Ambrish Mithal decodes Ozempic and other GLP-1 drugs, with Raj Ganpath
Endocrinologist Dr Ambrish Mithal, the author of the recently-released book, The Weight Loss Revolution, talks to fitness and ...
BMJ6d
Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is), originally developed for type 2 diabetes treatment, have demonstrated in randomised ...
Can Ozempic and other GLP-1 drugs be substitute for work outs? Dr Ambrish Mithal and Raj Ganpath discuss
Endocrinologist Dr Ambrish Mithal, the author of the recently-released book, The Weight Loss Revolution, talks to fitness and ...
EurekAlert!27d
Popular diabetes and weight-loss drug may reduce risk of dementia
Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and helps regulate blood sugar in T2D, is also the active component in the diabetes and weight-loss drugs ...
BioWorld7d
Triple agonist monomeric peptide shows distinct beneficial metabolic effects
Single agonists of the glucagon-like peptide-1 receptor (GLP-1R) have been a success in the treatment of obesity, but monomeric dual or triple agonists have demonstrated improved efficacy on energy ...
Healio8d
Resmetirom, glucagon receptor agonists appear similarly effective for MASLD, MASH
In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...